Evidence map›Paper›PMID 19352495›Full record

ArticlePloS one2009

The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome.

Victoria M Virador, Ben Davidson, Josephine Czechowicz, Alisha Mai, Jareer Kassis, Elise C Kohn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [BAG family gene and its relationship with lung adenocarcinoma susceptibility].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Victoria M ViradorMolecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America. vvirador@helix.nih.gov
Ben Davidson
Josephine Czechowicz
Alisha Mai
Jareer Kassis
Elise C Kohn
National Cancer Institute · USCenter for Cancer Research · US

Funding

Signal Transduction Therapy--Basic ScienceZIASC009163 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI KOHN, ELISE C. · 2009 to 2013
$1.4M
SIGNAL TRANSDUCTION THERAPY--BASIC SCIENCEZ01SC009163 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI KOHN, ELISE C. · 1996 to 2008
$506k
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundCaspase-mediated cleavage and proteasomal degradation of ubiquitinated proteins are two independent mechanisms for the regulation of protein stability and cellular function. We previously reported BAG3 overexpression protected ubiquitinated clients, such as AKT, from proteasomal degradation and conferred cytoprotection against heat shock. We hypothesized that the BAG3 protein is regulated by proteolysis. METHODOLOGY/PRINCIPAL

findingsStaurosporine (STS) was used as a tool to test for caspase involvement in BAG3 degradation. MDA435 and HeLa human cancer cell lines exposed to STS underwent apoptosis with a concomitant time and dose-dependent loss of BAG3, suggesting the survival role of BAG3 was subject to STS regulation. zVAD-fmk or caspase 3 and 9 inhibitors provided a strong but incomplete protection of both cells and BAG3 protein. Two putative caspase cleavage sites were tested: KEVD (BAG3(E345A/D347A)) within the proline-rich center of BAG3 (PXXP) and the C-terminal LEAD site (BAG3(E516A/D518A)). PXXP deletion mutant and BAG3(E345A/D347A), or BAG3(E516A/D518A) respectively slowed or stalled STS-mediated BAG3 loss. BAG3, ubiquitinated under basal growth conditions, underwent augmented ubiquitination upon STS treatment, while there was no increase in ubiquitination of the BAG3(E516A/D518A) caspase-resistant mutant. Caspase and proteasome inhibition resulted in partial and independent protection of BAG3 whereas inhibitors of both blocked BAG3 degradation. STS-induced apoptosis was increased when BAG3 was silenced, and retention of BAG3 was associated with cytoprotection. CONCLUSIONS/SIGNIFICANCE: BAG3 is tightly controlled by selective degradation during STS exposure. Loss of BAG3 under STS injury required sequential caspase cleavage followed by polyubiquitination and proteasomal degradation. The need for dual regulation of BAG3 in apoptosis suggests a key role for BAG3 in cancer cell resistance to apoptosis.

Indexed as

Adaptor Proteins, Signal TransducingApoptosisApoptosis Regulatory ProteinsCaspasesCell Line, TumorGene SilencingHumansHydrolysisProteasome Endopeptidase ComplexUbiquitinationAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsBAG3 protein, humanCaspasesProteasome Endopeptidase Complex

Identifiers

PMID19352495
PMCPMC2662420
OpenAlexW2077442319

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.